Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS

Takashi Ishida, Yoshiyuki Ishii, Masashi Tsuruta, Koji Okabayashi, Shingo Akimoto, Kaoru Koishikawa, Hirotoshi Hasegawa, Yuukou Kitagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Combination treatment with cetuximab and CPT-11 produces beneficial and synergistic effects in wild-type RAS metastatic colorectal cancer (mCRC) patients. However, the mechanism underlying this synergism is not yet understood. We examined whether cetuximab had a synergistic effect with CPT-11 and its active metabolite, SN38, and examined the molecular mechanism of the synergism between cetuximab and SN38 in CRC cells with various mutational status. We hypothesized that cetuximab promotes sensitivity to SN38 via suppression of heat shock protein 27 (HSP27), a protein involved in multidrug resistance through blocking the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, which is associated with chemosensitivity. Four human CRC cell lines with different RAS and BRAF mutational status were used. Expression levels of HSP27 protein correlated with SN38 sensitivity in these cell lines (R=0.841, p=0.159). Exposure to cetuximab and various concentration of AG490, an inhibitor of JAK2, STAT3 and HSP27 protein levels, except in the KRAS G12V mutant line, SW620. A synergistic effect of cetuximab in combination with SN38 was observed in RAS and BRAF wild-type cells (here, Caco2), but not in the three other RAS-or BRAFmutated cell lines. These results indicate that cetuximab may promote sensitivity to SN38 via suppression of HSP27 through blocking the JAK/STAT pathway in Caco2 cells. The mutational status of numerous downstream effectors, such as RAS and BRAF, is important in mono-or combination therapy with cetuximab. In conclusion, cetuximab may promote SN38 sensitivity via suppression of HSP27, through blocking the JAK/STAT signaling pathway, and shows synergistic effects when combined with SN38 in wild-type RAS CRC cells.

Original languageEnglish
Pages (from-to)926-932
Number of pages7
JournalOncology Reports
Volume38
Issue number2
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

HSP27 Heat-Shock Proteins
Colorectal Neoplasms
irinotecan
Janus Kinases
Transducers
Cell Line
Cetuximab
Proteins
Multiple Drug Resistance

Keywords

  • Cetuximab
  • Colorectal cancer
  • Heat shock protein 27
  • SN38
  • STAT3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS. / Ishida, Takashi; Ishii, Yoshiyuki; Tsuruta, Masashi; Okabayashi, Koji; Akimoto, Shingo; Koishikawa, Kaoru; Hasegawa, Hirotoshi; Kitagawa, Yuukou.

In: Oncology Reports, Vol. 38, No. 2, 01.08.2017, p. 926-932.

Research output: Contribution to journalArticle

Ishida, Takashi ; Ishii, Yoshiyuki ; Tsuruta, Masashi ; Okabayashi, Koji ; Akimoto, Shingo ; Koishikawa, Kaoru ; Hasegawa, Hirotoshi ; Kitagawa, Yuukou. / Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS. In: Oncology Reports. 2017 ; Vol. 38, No. 2. pp. 926-932.
@article{3e584bbdca274ad8a782afbdd98fecfd,
title = "Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS",
abstract = "Combination treatment with cetuximab and CPT-11 produces beneficial and synergistic effects in wild-type RAS metastatic colorectal cancer (mCRC) patients. However, the mechanism underlying this synergism is not yet understood. We examined whether cetuximab had a synergistic effect with CPT-11 and its active metabolite, SN38, and examined the molecular mechanism of the synergism between cetuximab and SN38 in CRC cells with various mutational status. We hypothesized that cetuximab promotes sensitivity to SN38 via suppression of heat shock protein 27 (HSP27), a protein involved in multidrug resistance through blocking the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, which is associated with chemosensitivity. Four human CRC cell lines with different RAS and BRAF mutational status were used. Expression levels of HSP27 protein correlated with SN38 sensitivity in these cell lines (R=0.841, p=0.159). Exposure to cetuximab and various concentration of AG490, an inhibitor of JAK2, STAT3 and HSP27 protein levels, except in the KRAS G12V mutant line, SW620. A synergistic effect of cetuximab in combination with SN38 was observed in RAS and BRAF wild-type cells (here, Caco2), but not in the three other RAS-or BRAFmutated cell lines. These results indicate that cetuximab may promote sensitivity to SN38 via suppression of HSP27 through blocking the JAK/STAT pathway in Caco2 cells. The mutational status of numerous downstream effectors, such as RAS and BRAF, is important in mono-or combination therapy with cetuximab. In conclusion, cetuximab may promote SN38 sensitivity via suppression of HSP27, through blocking the JAK/STAT signaling pathway, and shows synergistic effects when combined with SN38 in wild-type RAS CRC cells.",
keywords = "Cetuximab, Colorectal cancer, Heat shock protein 27, SN38, STAT3",
author = "Takashi Ishida and Yoshiyuki Ishii and Masashi Tsuruta and Koji Okabayashi and Shingo Akimoto and Kaoru Koishikawa and Hirotoshi Hasegawa and Yuukou Kitagawa",
year = "2017",
month = "8",
day = "1",
doi = "10.3892/or.2017.5734",
language = "English",
volume = "38",
pages = "926--932",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS

AU - Ishida, Takashi

AU - Ishii, Yoshiyuki

AU - Tsuruta, Masashi

AU - Okabayashi, Koji

AU - Akimoto, Shingo

AU - Koishikawa, Kaoru

AU - Hasegawa, Hirotoshi

AU - Kitagawa, Yuukou

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Combination treatment with cetuximab and CPT-11 produces beneficial and synergistic effects in wild-type RAS metastatic colorectal cancer (mCRC) patients. However, the mechanism underlying this synergism is not yet understood. We examined whether cetuximab had a synergistic effect with CPT-11 and its active metabolite, SN38, and examined the molecular mechanism of the synergism between cetuximab and SN38 in CRC cells with various mutational status. We hypothesized that cetuximab promotes sensitivity to SN38 via suppression of heat shock protein 27 (HSP27), a protein involved in multidrug resistance through blocking the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, which is associated with chemosensitivity. Four human CRC cell lines with different RAS and BRAF mutational status were used. Expression levels of HSP27 protein correlated with SN38 sensitivity in these cell lines (R=0.841, p=0.159). Exposure to cetuximab and various concentration of AG490, an inhibitor of JAK2, STAT3 and HSP27 protein levels, except in the KRAS G12V mutant line, SW620. A synergistic effect of cetuximab in combination with SN38 was observed in RAS and BRAF wild-type cells (here, Caco2), but not in the three other RAS-or BRAFmutated cell lines. These results indicate that cetuximab may promote sensitivity to SN38 via suppression of HSP27 through blocking the JAK/STAT pathway in Caco2 cells. The mutational status of numerous downstream effectors, such as RAS and BRAF, is important in mono-or combination therapy with cetuximab. In conclusion, cetuximab may promote SN38 sensitivity via suppression of HSP27, through blocking the JAK/STAT signaling pathway, and shows synergistic effects when combined with SN38 in wild-type RAS CRC cells.

AB - Combination treatment with cetuximab and CPT-11 produces beneficial and synergistic effects in wild-type RAS metastatic colorectal cancer (mCRC) patients. However, the mechanism underlying this synergism is not yet understood. We examined whether cetuximab had a synergistic effect with CPT-11 and its active metabolite, SN38, and examined the molecular mechanism of the synergism between cetuximab and SN38 in CRC cells with various mutational status. We hypothesized that cetuximab promotes sensitivity to SN38 via suppression of heat shock protein 27 (HSP27), a protein involved in multidrug resistance through blocking the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, which is associated with chemosensitivity. Four human CRC cell lines with different RAS and BRAF mutational status were used. Expression levels of HSP27 protein correlated with SN38 sensitivity in these cell lines (R=0.841, p=0.159). Exposure to cetuximab and various concentration of AG490, an inhibitor of JAK2, STAT3 and HSP27 protein levels, except in the KRAS G12V mutant line, SW620. A synergistic effect of cetuximab in combination with SN38 was observed in RAS and BRAF wild-type cells (here, Caco2), but not in the three other RAS-or BRAFmutated cell lines. These results indicate that cetuximab may promote sensitivity to SN38 via suppression of HSP27 through blocking the JAK/STAT pathway in Caco2 cells. The mutational status of numerous downstream effectors, such as RAS and BRAF, is important in mono-or combination therapy with cetuximab. In conclusion, cetuximab may promote SN38 sensitivity via suppression of HSP27, through blocking the JAK/STAT signaling pathway, and shows synergistic effects when combined with SN38 in wild-type RAS CRC cells.

KW - Cetuximab

KW - Colorectal cancer

KW - Heat shock protein 27

KW - SN38

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=85022022104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022022104&partnerID=8YFLogxK

U2 - 10.3892/or.2017.5734

DO - 10.3892/or.2017.5734

M3 - Article

C2 - 28656305

AN - SCOPUS:85022022104

VL - 38

SP - 926

EP - 932

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -